carboplatin + nab-paclitaxel + pirfenidone

The combination of carboplatin + nab-paclitaxel + pirfenidone is a treatment regimen that has been studied for patients with non-small cell lung cancer (NSCLC) who also have interstitial lung disease (ILD), particularly idiopathic pulmonary fibrosis (IPF). This combination therapy aims to treat the cancer while preventing acute exacerbations of the underlying lung disease. ## Components and Mechanism This combination consists of three distinct medications: 1. **Carboplatin**: A platinum-based chemotherapy agent that works by binding to DNA and interfering with cell division, primarily targeting rapidly dividing cancer cells[1][2]. 2. **Nab-paclitaxel**: A nanoparticle albumin-bound form of paclitaxel (also known as Abraxane) that inhibits microtubule disassembly, preventing cancer cell division. It has a mean particle size of 130 nm and achieves higher concentrations of free paclitaxel in serum compared to solvent-based paclitaxel[7]. 3. **Pirfenidone**: An antifibrotic agent used for treating idiopathic pulmonary fibrosis. It appears to have a prophylactic effect against chemotherapy-associated acute exacerbations of IPF when combined with chemotherapy regimens[1][2]. ## Clinical Evidence Studies have investigated this combination therapy with promising results: - A study found that pirfenidone combined with carboplatin-based regimens might be safe as first-line chemotherapy for patients with IPF and NSCLC[1][2]. - None of the patients who received pirfenidone in combination with first-line carboplatin-based chemotherapy developed acute IPF exacerbations in one study[2]. - The median progression-free survival (PFS) for lung cancer was reported as 110 days (95% CI: 57-199 days), while the median overall survival (OS) was 362 days (95% CI: 220-526 days) in patients receiving this combination[2]. - PFS for IPF was 447 days (95% CI: 286-indeterminate days), and the cumulative incidence of acute exacerbations of IPF within one year was 18%[2]. ## Administration In clinical studies, the regimen was administered as follows: - Carboplatin (area under the curve = 5) on day 1 - Nab-paclitaxel (100 mg/m²) on days 1, 8, and 15 every 4 weeks - Pirfenidone administered continuously throughout treatment[1][5] Some studies used a dosing schedule for pirfenidone starting at 100 mg three times daily for 7 days, then 200 mg three times daily for 14 days, followed by a maintenance dose of 300 mg three times daily[6]. ## Safety Profile The combination appears to have a manageable safety profile: - Hematological toxicity requires careful monitoring[4]. - The addition of pirfenidone to carboplatin-based regimens appears to reduce the risk of acute exacerbations of IPF during chemotherapy[1][2]. - In one study, the completion rate of ≥4 cycles of carboplatin and nab-paclitaxel was 76% (95% confidence interval: 56.2%–88.8%)[5]. This combination represents an important treatment option for patients with the challenging comorbidity of NSCLC and ILD, where treatment options have historically been limited due to the risk of chemotherapy triggering acute exacerbations of the underlying lung disease.